Science Explorer Back to mapMap
Discussion
Researcher · Narodowy Instytut Leków · Poland

Sylwia Flis

Sylwia Flis publishes mostly in Hematology, Molecular Biology and Biomedical Engineering, on topics such as Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research and Acute Myeloid Leukemia Research.

ORCID 0000-0002-6071-9952 OpenAlex
World rank
#2,245,863
of 7,710,434 ranked researchers
Rank in Poland
#13,592
of 100,960
Works
41
Citations
1.4k
Citations per work
33.3
h-index
20
i10-index 22Top 24% in Hematology
Sylwia Flis

What does Sylwia Flis research?

Sylwia Flis's work is mostly in Medicine (37%), Biochemistry, Genetics and Molecular Biology (16%), Engineering (8%).

Everything else: 16 works · 39.5% of their workHealth Sciences: 15 works · 36.8% of their workMedicine: 15 works · 36.8% of their workHematology: 7 works · 17.5% of their workOncology: 3 works · 7.9% of their workGenetics: 3 works · 7.0% of their workPublic Health, Environmental and Occupational Health: 2 works · 4.4% of their workLife Sciences: 6 works · 15.8% of their workBiochemistry, Genetics and Molecular Biology: 6 works · 15.8% of their workMolecular Biology: 6 works · 15.8% of their workPhysical Sciences: 3 works · 7.9% of their workEngineering: 3 works · 7.9% of their workBiomedical Engineering: 3 works · 7.9% of their workTHEIR WORKSylwia Flis41works
Life Sciences16%Physical Sciences8%Health Sciences37%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else1639.5%
    1. Medicine1536.8%
    1. Biochemistry, Genetics and Molecular Biology615.8%
    1. Engineering37.9%
  1. 1Hematology18% of their works
  2. 2Molecular Biology16% of their works
  3. 3Biomedical Engineering8% of their works
  4. 4Oncology8% of their works
  5. 5Genetics7% of their works
  6. 6Public Health, Environmental and Occupational Health4% of their works

Research topics

Which keywords describe Sylwia Flis's research?

The keywords of their largest research topics: Prognostic Factors, BCR-ABL, Imatinib, Chronic Lymphocytic Leukemia, Genomic Aberrations, Acute Myeloid Leukemia, AML and Acute Lymphoblastic Leukemia.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Prognostic Factors183 topics
  2. BCR-ABL141 topic
  3. Imatinib141 topic
  4. Chronic Lymphocytic Leukemia71 topic
  5. Genomic Aberrations71 topic
  6. AML61 topic
  7. Acute Myeloid Leukemia61 topic
  8. Acute Lymphoblastic Leukemia51 topic
  9. Childhood Cancer51 topic
  10. DNA Methylation51 topic
  11. Histone Modification51 topic
  12. HDAC Inhibitors41 topic
  13. Histone Deacetylases41 topic
  14. BET Bromodomains31 topic
  15. Bioprinting31 topic
  16. PROTACs31 topic
  17. Tissue Engineering31 topic

Where does Sylwia Flis work?

Sylwia Flis's main affiliation in the publication record is Narodowy Instytut Leków, Poland.

How many publications and citations does Sylwia Flis have?

OpenAlex counts 41 works and 1,367 citations for Sylwia Flis, an h-index of 20, ranking #2,245,863 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Sylwia Flis. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.